Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bioceres Crop Solutions (BIOX) Receivables (2017 - 2025)

Bioceres Crop Solutions' Receivables history spans 9 years, with the latest figure at $188.4 million for Q2 2025.

  • For Q2 2025, Receivables fell 16.48% year-over-year to $188.4 million; the TTM value through Jun 2025 reached $188.4 million, down 16.48%, while the annual FY2025 figure was $188.4 million, 16.48% down from the prior year.
  • Receivables for Q2 2025 was $188.4 million at Bioceres Crop Solutions, down from $225.6 million in the prior quarter.
  • Across five years, Receivables topped out at $225.6 million in Q2 2024 and bottomed at $13.2 million in Q4 2021.
  • The 5-year median for Receivables is $159.0 million (2022), against an average of $140.9 million.
  • The largest annual shift saw Receivables soared 42.53% in 2023 before it fell 16.48% in 2025.
  • A 5-year view of Receivables shows it stood at $13.2 million in 2021, then skyrocketed by 892.2% to $131.1 million in 2022, then skyrocketed by 42.53% to $186.8 million in 2023, then grew by 20.76% to $225.6 million in 2024, then dropped by 16.48% to $188.4 million in 2025.
  • Per Business Quant, the three most recent readings for BIOX's Receivables are $188.4 million (Q2 2025), $225.6 million (Q2 2024), and $186.8 million (Q2 2023).